G1 Therapeutics

204 articles about G1 Therapeutics

• G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference

  11/23/2022

  G1 Therapeutics, Inc. today announced that Jack Bailey, G1’s Chief Executive Officer, and other members of the executive team will participate virtually in the Evercore ISI HealthCONx Conference. The fireside chat with G1 will be held at 1:25PM EST on November 30, 2022.

• G1 Therapeutics Announces Closing of Offering of Common Stock

  11/22/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the closing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share.

• G1 Therapeutics Announces Pricing of Offering of Common Stock - November 18, 2022

  11/18/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the pricing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share, for total gross proceeds of $50,050,000.

• G1 Therapeutics Announces Proposed Public Offering of Common Stock - November 17, 2022

  11/17/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced that it has commenced an underwritten public offering of its common stock.

• Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)

  11/2/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, described safety data from the first 18 patients enrolled in its ongoing Phase 2, single arm study of trilaciclib administered prior to the antibody-drug conjugate, sacituzumab govitecan-hziy in patients with unresectable locally advanced or metastatic triple-negative breast cancer.

• G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights

  11/2/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the third quarter ended September 30, 2022.

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 01, 2022

  11/1/2022

  G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for 5,200 shares of G1’s common stock and 3,400 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

• G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer

  10/26/2022

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it is supporting a Phase 2 investigator initiated study (ISS) of trilaciclib and lurbinectedin in patients with extensive stage small cell lung cancer (ES-SCLC).

• G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022

  10/19/2022

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2022 on Wednesday, November 2, 2022, at 8:30 a.m. ET.

• G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)

  10/10/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the last patient has been randomized in PRESERVE 2, G1’s Phase 3 clinical trial of trilaciclib in patients with metastatic triple negative breast cancer receiving chemotherapy.

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2022

  10/3/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 44,300 shares of G1’s common stock and 29,400 restricted stock units to three hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

• G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference

  9/7/2022

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive Officer, and other members of the executive team will participate virtually in the H.C. Wainwright 24th Annual Global Investment Conference.

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2022

  9/1/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 10,000 shares of G1’s common stock and 6,600 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

• G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights

  8/3/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the second quarter ended June 30, 2022.

• G1 Therapeutics to Participate Virtually in the 2022 BTIG Biotechnology Conference and the 2022 Wedbush Pacgrow Healthcare Conference

  8/1/2022

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in August 2022.

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 01, 2022

  8/1/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 10,800 shares of G1’s common stock and 7,200 restricted stock units to two hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

• G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors

  7/25/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the appointment of Norman E. “Ned” Sharpless, M.D., to its Board of Directors.

• G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022

  7/20/2022

  G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2022 on Wednesday, August 3, 2022, at 8:30 a.m. ET.

• COSELA®, the World's First Comprehensive Myeloprotection Drug against Chemotherapy Damage, Wins Approval in China

  7/18/2022

  On July 13 2022, Simcere Pharmaceuticals announced that the China National Medical Products Administration has conditionally approved COSELA®, an innovative myeloprotection drug jointly developed in China by Simcere and G1 Therapeutics.

• COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  7/13/2022

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the China National Medical Products Administration (NMPA) has conditionally approved COSELA (trilaciclib hydrochloride for injection), which was jointly developed for use in Greater China by Simcere and G1 Therapeutics.